x

Society

AstraZeneca Clot Worries Scare Many Greeks Off COVID-19 Vaccine

ATHENS – Losing trust over reports of rare blood clots and mixed messages about the safety of the AstraZeneca COVID-19 vaccine, some Greeks are canceling or not showing up for their appointments to be inoculated.The European Union drug regulator said Wednesday there is a link between AstraZeneca’s Covid-19 vaccine and very rare blood clots in the brain but almost immediately a 63-year-old woman in Greece reportedly suffered one after a shot.

Some 364,000 people in Greece had received the first dose of the AstraZeneca vaccine by April 5 but two are required almost three months apart and about  605,000 of the next 2,450,000 vaccinations are to be with that dose.

Vaccine clinics are reporting that no-shows are 3 percent higher for AstraZeneca vaccinations compared to the Pfizer and Moderna version which are taken three and four weeks apart.

Cancellation rates are also up three percent for AstraZeneca, three times higher than for Pfizer and Moderna, said Kathimerini in a report on the growing worry that Greek and EU health officials are trying to assuage.

“We administered 60 vaccinations per day when we started,” Alexia Grigoropoulou, a senior health official at the Zacharo vaccination center in the Peloponnese told the paper. “Now we are down to 40 or 30 per day,” she said of the dilemma.

RELATED

ATHENS - No way of telling how much they liked it or were too looped to walk out, but a hungry flock of sheep in central Greece looking for food when rains flooded the region found - and ate - 100 kilos (222 pounds) of marijuana in a greenhouse.

Top Stories

Columnists

A pregnant woman was driving in the HOV lane near Dallas.

General News

FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.

Video

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. [email protected]

You may unsubscribe at any time using the link in our newsletter.